Drug Type Small molecule drug |
Synonyms Castrodin, Gastrodin, Gastrodini Synthici + [13] |
Target |
Action inhibitors, stimulants |
Mechanism GFAP inhibitors(Glial fibrillary acidic protein inhibitors), PI3K family stimulants(Phosphatidylinositol 3-kinase family stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 2001), |
Regulation- |
Molecular FormulaC13H18O7 |
InChIKeyPUQSUZTXKPLAPR-UJPOAAIJSA-N |
CAS Registry62499-27-8 |
Start Date20 Jun 2026 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator- |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Gastrodine | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Brain Injuries, Traumatic | China | 01 Jan 2001 | |
| Headache | China | 01 Jan 2001 | |
| Neurasthenia | China | 01 Jan 2001 | |
| Vertigo | China | 01 Jan 2001 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Delirium | Phase 1 | China | 04 Mar 2026 | |
| Colitis, Ulcerative | Preclinical | China | 01 Sep 2025 | |
| Hypercholesterolemia | Preclinical | China | 01 Jul 2025 | |
| Hypoxia-Ischemia, Brain | Preclinical | China | 06 May 2025 | |
| Nervous System Diseases | Preclinical | China | 18 Mar 2025 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
No Data | |||||||









